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Abstract
Background: Motor and cognitive deficits and consequently mobility problems are common in geriatric patients.
The currently available methods for diagnosis and for the evaluation of treatment in this vulnerable cohort are
limited. The aims of the ComOn (COgnitive and Motor interactions in the Older populatioN) study are (i) to define
quantitative markers with clinical relevance for motor and cognitive deficits, (ii) to investigate the interaction
between both motor and cognitive deficits and (iii) to assess health status as well as treatment outcome of 1000
geriatric inpatients in hospitals of Kiel (Germany), Brescia (Italy), Porto (Portugal), Curitiba (Brazil) and Bochum
(Germany).
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Methods: This is a prospective, explorative observational multi-center study. In addition to the comprehensive
geriatric assessment, quantitative measures of reduced mobility and motor and cognitive deficits are performed
before and after a two week’s inpatient stay. Components of the assessment are mobile technology-based
assessments of gait, balance and transfer performance, neuropsychological tests, frailty, sarcopenia, autonomic
dysfunction and sensation, and questionnaires to assess behavioral deficits, activities of daily living, quality of life,
fear of falling and dysphagia. Structural MRI and an unsupervised 24/7 home assessment of mobility are performed
in a subgroup of participants. The study will also investigate the minimal clinically relevant change of the
investigated parameters.
Discussion: This study will help form a better understanding of symptoms and their complex interactions and
treatment effects in a large geriatric cohort.
Keywords: Balance, Body-worn sensors, Wearables, Comprehensive geriatric assessment, Executive function, Gait,
Older adults, Quantitative assessment
Background
The demographic changes associated with increased life-
expectancy have led to a substantial increase in older
people suffering from multimorbidity with age-related
neurological diseases and functional impairment [1–3]. A
target-oriented and specific geriatric treatment designed
by a multiprofessional and –disciplinary team including
neurological expertise, addressing both the clinical rele-
vant functional deficits and the individual needs of the pa-
tients, is urgently needed [4, 5]. Impaired gait, balance,
cognitive functions and, consequently, reduced mobility
and falls are among the most relevant age-related func-
tional impairments associated with multimorbidity. At 70
years, the prevalence of gait disorders is about 35% and in-
creases further with age [6]. About one third of people
aged 65 years or above fall at least once a year [7]. Inter-
estingly, the prevalence of falls among neurological pa-
tients is nearly twice as high as in the general population
[8]. Of these patients, 5–10% develop serious injuries, e.g.
fractures and head trauma [9, 10]. Delayed recovery from
fall-related injury in geriatric patients often requires long-
lasting inpatient stays with high resource costs [11–13]
and the possibility of complications such as pneumonia.
Moreover, long-term morbidity associated with fear of
falling affect quality of life and mobility [14–16].
Cognition, particularly executive functions, are also
often affected in older adults [17, 18] and can interfere
with daily life activities and influence mortality rates. In
an 8-year follow-up study [19], people with deficits in
executive functions had a higher mortality rate than
those without. One reason may be the reduced ability to
manage multiple medical conditions [19]. Executive dys-
functions even affect intervention outcomes. For ex-
ample, a recent study showed that baseline executive
function performance predicted performance on the mo-
bility tests after training in older adults [20].
A growing amount of epidemiological and patho-
physiological studies suggests that motor and cognitive
deficits interact and amplify each other [14, 18, 21, 22].
The interaction is not surprising as: (i) recent neuroim-
aging studies indicate a strong involvement of, e.g. the
thalamus, basal ganglia, cerebellum, mesiotemporal areas
and the frontal cortex in gait and balance performance
[23, 24], and (ii) lesions in these areas are associated
with falls, e.g. for Parkinson patients [25–27].
Physical activity may depend on brain integrity and in-
fluences geriatric conditions, such as frailty. A recent
study indicates that physical activity interventions can
reduce the prevalence and severity of frailty in elderly
people [28]. A post-mortem study showed that white
matter lesions of the brain explained 4% of the variance
of physical frailty in 165 participants with a mean age at
death of 88 years [29]. However, the interaction between
physical activity and age-associated functional impair-
ment, such as motor and cognitive deficits and frailty,
remain largely unexplained and need further investiga-
tion. Research and clinical routine commonly use quali-
tative measures for the assessment of mobility, and
motor and cognitive deficits, and these tools improved
our understanding of these symptoms. However, these
tools have numerous disadvantages, such as inaccuracy,
high time expenditure and investigator dependency [30].
Due to the dynamic development in the fields of life
sciences and technology, quantitative measures to evalu-
ate impairment of gait, balance, cognitive functions and
mobility –including mobile technology, so-called “wear-
ables”- are increasingly available also for medical pur-
poses. This technology can generate highly accurate
outcome parameters for clinical studies and is even close
to be implemented in the clinical routines [30–33].
The first mayor aim of this prospective, explorative
observational multi-center study is therefore to explore
quantitative markers of gait, balance and cognitive defi-
cits in relation to routine clinical and specific geriatric
parameters –as assessed with the comprehensive geriat-
ric assessment (CGA)- in a large cohort of geriatric
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patients with predominantly chronic neurologic condi-
tions. Detailed information beyond usual CGA parame-
ters, e.g. gait variability, step characteristics, postural
control and (semi-)quantitative cognitive parameters
could substantially improve our understanding of geriat-
ric conditions [30]. We will also determine the minimal
detectable and clinical relevant change of many of the
parameters investigated.
The second mayor aim of the study is to examine the
association between executive and attentional deficits
and the identified quantitative motor parameters in this
vulnerable clinical cohort. We hypothesize that these
cognitive deficits have predictive value for certain gait
and balance deficits. The third mayor main aim is to
evaluate the efficacy of an individualized geriatric in-
patient treatment. The large dimension and multifaceted
construction of the dataset will also allow many add-
itional hypotheses to be tested.
Novel aspects of this study are (i) the recruitment of a
prospective and large geriatric cohort, (ii) the coverage
of a broad range of clinically relevant parameters, (iii)
the identification of stabile quantitative parameters with
clinical relevance, (iv) the evaluation of treatment re-
sponse, (v) the definition of the minimal clinically rele-
vant change (MCRC) of the investigated parameters, (vi)
the inclusion of newest mobile technology for the assess-
ment of mobility, motor functions and balance aspects
using validated algorithms, and (vii) the assessment of
this vulnerable cohort at places beyond the clinical
environment.
Methods/design
Ethics
Ethical approvals have been obtained from the ethical
committees of Kiel, Brescia, Porto, Curitiba and
Bochum. The centres have submitted their proposals ac-
cording to the principles of the Declaration of Helsinki.
All participants will receive detailed oral and written in-
formation about the content and procedure of the study.
Participants
The study will include geriatric patients aged 70 years
and older, with and without neurological conditions
[34–36]. Patients aged between 50 and 69 years will also
be considered if they suffer from at least two chronic
conditions [35]. Additional inclusion criteria are the abil-
ity to stand without personal aid for at least ten seconds
and to walk at least three meters (walking aids permit-
ted). Exclusion criteria are severe deficits in conscious-
ness (clinical diagnosis), more than two falls during the
previous week (fall risk during the assessment too high),
five points or less in the Montreal Cognitive Assessment
(MoCA) test [37, 38], history of or current drug abuse
(except nicotine) and (corrected) visual acuity below
60% (assessed using a Sloan Letter Chart for three meter
distance [39]). Magnetic Resonance Imaging (MRI) will be
performed in a subset of patients having a clinical indica-
tion for this examination. Participants suffering from
claustrophobia, or having pacemakers, defibrillators, tar-
geted drug delivery systems, deep brain stimulation, vena
cava filters, cochlear implants or any kind of ferromag-
netic material within the body will not be considered. The
cohort will include inpatients treated in University and
General hospitals and geriatric rehabilitation centres.
Procedure
This is a prospective, explorative observational multi-
center study. Most of the participants will be recruited
at admission. A subsample (n = 100) with a planned hos-
pital stay (e.g. to evaluate new treatment options or to
improve medication plans in severely affected patients
that are at risk of losing functional independency) will
be contacted via telephone, to ask them whether they
would be interested to participate in a one week home-
based assessment with wearables before and after the
treatment phase. All participants will be assessed within
the first two days (T1) and during the last two days be-
fore discharge (T2) of their inpatient stay. To determine
the Minimal Detectable Change, an additional subgroup
(n = 100) will undergo a visit (T0) 24 h before or after
T1. Inpatient’s stay will be approximately 14–20 days.
All participants will receive multidisciplinary care with
an individually adapted set of therapeutic options de-
pending on their needs during their inpatient treatment.
Data obtained from T1 will be used to evaluate cross-
sectional aspects of the study. Response to treatment will
be evaluated by calculating the change between T1 and
T2 after an approximately 14–20 days multidisciplinary
treatment. Figure 1 illustrates the detailed study design.
Measures
All participants will undergo an extensive and quantita-
tively oriented CGA, i.e. an assessment that collects
information about all five relevant components of the
International Classification of Functioning, Disability
and Health (ICF) model [40]. Furthermore, a detailed
evaluation of mobility, and specific motor and cognitive
function will be conducted. For measurements of motor
and cognitive parameters, translated and validated test
versions will be used as far as available. Clinical and
demographical data and questionnaires will also be
assessed in the required languages.
Clinical and demographic data
Clinical and demographic data –including age, gender,
diagnosis, initial and current symptoms, concomitant dis-
eases, activities of daily living (ADL, [41]), instrumental
ADL (iADL, [42]), nutritional aspects and medication–
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will be collected from clinical records and also with a
semi-standardized clinical interview. Neurological routine
assessment will include evaluation of strength (grip force),
muscular proprioceptive reflexes, pallaesthesia, signs of
ataxia, and frontal lobe dysfunction. We will use the
Geriatrie-Check, which is a screening tool for the identifi-
cation of geriatric patients [43, 44] and assesses aspects of
dementia, level of care, frailty, and the premorbid level. It
has recently been validated [44]. We will also use the geri-
atric screening according to Lachs et al. [45] to evaluate
the functional aspects of vision, hearing, and urinary in-
continence. Self-care and mobility skills (e.g. toilet use,
eating, dressing, climbing stairs) will be appraised by the
commonly used and reliable (kappa = 0.93) Barthel Index
[46, 47]. Subjective improvement will be assessed using
the Clinical Global Impression - Global Improvement -
Scale (CGI-I, [48]).
Diagnoses and medication will be extracted from the
medical reports. Extent of treatment and rehabilitation
-as a covariate- will be evaluated using number and
duration of therapeutic sessions as well as (change of)
medication and medical aids.
Cognition
Cognitive functions will be measured with standardized
neuropsychological screening tools and tests. We will
use the MoCA for the evaluation of global cognitive per-
formance. The MoCA has been shown to be internally
consistent (Cronbach’s alpha = 0.83) and highly sensitive
in detecting Mild Cognitive Impairment (MCI, 90%) and
Alzheimer’s Disease (100%). Normative and validation
data are available for Brazilian, Italian, German and
Portuguese populations [38, 49–51]. For the assessment
of frontal-executive dysfunctions the required version of
the Frontal Assessment Battery (FAB) will be used
[52–54]. The FAB consists of six items, testing as-
pects of conceptualization, lexical fluency, motor pro-
gramming, sensitivity to interference, inhibitory control
and environmental autonomy.
The Trail Making Test (TMT, [55]) assesses visual
scanning and processing speed (TMT part A) as well as
mental flexibility and divided attention ((TMT part B, B-
A). Construct validity of the TMT is good [56] and there
are normative data available stratified by age and educa-
tion for the required languages [57–60].
In order to gain the second study aim in more detail
regarding specific cognitive functions, the Kiel centre
will perform a detailed neuropsychological testing in this
subcohort, including the following tests:
– The Testbatterie zur Aufmerksamkeitsprüfung (TAP,
[61]) is a computer-based assessment battery for
Fig. 1 Study flowchart. Overview of the study including visits and relevant assessments. CS: Cross-sectional, MCRC: Minimal clinically relevant
change, RTT: Response to treatment, T1: Baseline assessment (before / at admission), T2: Follow-up assessment (at / after discharge), T0: Time of
assessment 0, for reliability / MCIC evaluation (24 h before or after T1)
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attention. We will use the subtest “Alertness” to
measure reaction time to a visual stimulus and the
capability to inhibit reactions to a pre-stimulus.
– The standardized Alters-Konzentrations-Test (AKT,
[62]) provides information about vigilance,
concentration and focused attention (the capacity to
focus on a stimulus while suppressing imposed
distractors). Retest-reliability is high (r = 0.75–0.89, [63]).
– The Five-Point Test (FPT, [64]) is a standardized
paper-pencil test for figural fluency and strategic
thinking. The test consists of five-dot boxes in six
rows on each sheet where participants produce as
many different figures as possible by connecting the
dots in each box within a defined time period. The
FPT is a valid test that has excellent inter-rater
(ICC = 0.99) and good test-retest reliability (ICC =
0.72–0.84, [64]).
– The Regensburger Wortflüssigkeitstest (RWT, [65])
assesses verbal fluency and flexibility. Subjects have
to name as many words as possible within two
minutes that (i) belong to a certain category, (ii)
have a defined starting letter, (iii) belong to two
different categories (alternating naming) and (iv)
have two defined starting letters (again alternating
naming). Inter-rater reliability of the test is excellent
(ICC = 0.99) and test-retest reliability good (rtt =
0.72 – rtt = 0.89, [65]).
– The Nürnberger-Alters-Inventar (NAI, [66]), normed
for people aged between 57 and 96 [66], provides
information about cognitive and behavioural aspects.
We will use the subtest Farb-Wort-Interferenz-Test
(FWIT), based on the widely used Stroop-Test, to
assess attention and cognitive flexibility during
provision of conflicting stimuli.
To avoid learning effects in T2, parallel versions of the
MoCA, the AKT and RWT will be provided.
Axial motor function
Gait, balance and transfer aspects will be measured in a
supervised environment (e.g., the ward, Fig. 2) using a
set of well-established tests (summarized in Table 1),
which will all be instrumented with CE-certified wear-
able devices (Rehagait®, Hasomed GmbH, Magdeburg,
Germany; sensors at the feet and on the lower back).
The protocol will include the Short Physical Performance
Battery (SPPB, [67–69]). The SPPB measures balance
(tandem, semi-tandem, and side-by-side stand), gait speed
(walking twice four meters at a comfortable speed) and
chair rise performance (5-Chair rise test, as fast as possible)
which has been shown to be reliable in older adults (ICC =
0.83–0.89, [70]). Participants will also perform the above-
mentioned balance tasks on a foam pad (Airex balance pad,
50x41x6 cm). This test has already been performed under
instrumented conditions with test-retest reliability (ICC)
between 0.41 and 0.81 [71].
Moreover, the Timed-up-and-Go test (TUG) will be
used to assess mobility aspects and turning. Recent
Fig. 2 Assessment of axial motor function. Simplified illustration of the standardized motor tasks. SPPB: Short Physical Performance Battery, TUG:
Timed-up-and-Go Test
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studies suggest that instrumentation of the TUG with
wearable devices can provide useful additional and
complementary information to the generally used
total time [68, 72–74].
Participants will also perform straight walks (out of a
standing position) over three meters and 20 m and
circular walks around a 1.20 m circle (360°). Single task
performance will be assessed during both walking condi-
tions with self-selected and as-fast-as-possible pace, ex-
cept for circular walking (self-selected pace starting with
the right leg and then with left leg). Dual task perform-
ance (checking boxes and subtracting serial 7 s) will be
assessed during circular walks in self-selected pace con-
dition, straight walking dual-task performance in fast
pace condition [75–77].
The functional reach (FR) test measures balance at the
limits of stability in the anterior direction. It can identify
fall risk and balance impairment in geriatric patients [78,
79]. We have recently published an instrumented version
of the test [79]. Participants will stand upright next to a
wall with a yardstick and put their right arm in a
stretched out position. Then they will reach forward as
far as they are able to, and then be asked to keep this
position for 15 s.
Part III of the revised version of the Unified Parkinson’s
Disease Rating Scale (MDS UPDRS-III, [80]) will be used
to assess axial deficits (e.g., via the postural instability and
gait (PIGD) subscore) and parkinsonian signs. The Hoehn
& Yahr scale will be used in patients with Parkinson’s dis-
ease (PD) to define disease severity [81].
The Falls Efficacy Scale (FES-I, [82]) consists of 16
questions about concerns regarding falling in specific ac-
tivities of daily living (e.g., when getting dressed, when
taking a shower or when shopping). The FES-I is a reli-
able instrument (Cronbach’s alpha = 0.79) and a strong
association with previous as well as future falls has been
found [82].
Fine motor function
The Functional Dexterity Test (FDT, pegboard test) is a
reliable and valid instrument to measure finger and
thumb movement [83]. Participants will turn 16 pegs in
a zigzag manner as fast as possible on a wooden board
with holes, first with the dominant, then with the non-
dominant hand.
The 20-Cents test assesses fine motor skills under
daily life conditions and is validated for geriatric patients
[84]. Twenty 1-cent coins, spread over a white sheet of
paper, will be picked up with each hand (first the domin-
ant one, then the non-dominant one) and put into a box
as fast as possible.
Health-related quality of life, behavior, social participation,
physical activity and pain
Health-Related Quality of Life (HrQoL, [85, 86]) is one
of the most important factors regarding treatment deci-
sions and outcome of treatment. Main dimensions of
HrQoL are physical, mental, social and role functioning.
The EuroQol questionnaire with five dimensions (EQ-
5D-5 L, [87]) consists of a descriptive part and the EQ
Visual Analogue Scale. For the descriptive part, partici-
pants rate the impact of mobility and its deficits, self-
care, usual activities, pain/ discomfort and anxiety/
depression on HrQoL. The EQ Visual Analogue Scale
allows the participant to rate today’s overall HrQoL
on a scale of 0 (worst health they can imagine) to
100 (best health).
The Depression im Alter scale (DIA-S, [88]) assesses
specific aspects of depression and consists of ten items.
The test person is asked to focus on the previous 14
days. The DIA-S is reliable (Cronbach’s alpha = 0.84)
and has been validated in geriatric patients [89].
Apathy, a common symptom in neurological and
psychiatric diseases, will be assessed with the German
version of the Apathy Evaluation Scale (AES-D, [90]).
The AES-D includes cognitive and emotional aspects of
goal-directed behaviour. A total of 18 items are rated on
a four-point Likert scale by the participant (AES-D-S,
self-rated) and by a relative (AES-D-I, informant). The
AES-D is reliable (Cronbach’s alpha = 0.91–0.94) and has
been shown to be valid in patients with diverse diseases
and in healthy adults [90].
The reliable (ICC = 0.70–0.94) and valid Nürnberger-
Alters-Alltagsaktivitäten-Skala (NAA), part of the NAI
[66], is a 20-item questionnaire for the assessment of
independency and participation in activities of daily
living.
Physical activity (PA) will be assessed with the self-
administered short version of the International Physical
Activity Questionnaire (IPAQ, [91]). The participants
are asked to estimate how much time in days per week
and in hours per weekday they spend doing: (i) vigorous
physical activities, (ii) moderate physical activities, (iii)
walking, and (iv) sitting. Detailed information about reli-
ability and validity are available for all versions from
over twelve countries [91].
Table 1 Tests of axial motor functions
Test Task
Short Physical
Performance Battery
Tandem, semi-tandem, side-by-side stand
Two 4-m-walks with comfortable speed
5-Chair rise test, as fast as possible
Timed-up-and-Go test
Straight walk
Circular walk
Rise from a chair, 3-m-walk, turning, walk back
Standing position, 3-m-walk, no turning
Standing position, 20-m-walk under single and
dual task conditions
Walk around a 1.20 m circle under single and
dual task conditions
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Pain will be assessed via the painDETECT Question-
naire (PD-Q), which is a reliable screening tool with high
sensitivity, specificity and positive predictive accuracy [92].
Sarcopenia, frailty and malnutrition
The Jamar hydraulic hand dynamometer (AFH, Lügde,
Germany) will be used to measure grip force [93]. Lean
body / muscle mass and total body water and fat will be
quantitatively assessed with the validated bioelectrical
impedance analysis (BIA, Akern Bia 101, SMT medical
GmbH & Co. KG, Würzburg, Germany, [94, 95]). The
BIA will be applied as instructed in the manual with four
electrodes (two at the right foot, two on the right hand)
in a lying position after a rest phase of about ten
minutes [96]. For the definition of sarcopenia we will
follow the definition of the European consensus on
definition and diagnosis for sarcopenia [97, 98].
Frailty will be assessed with the FRAIL-scale, a five-
item questionnaire asking for fatigue, resistance, ambula-
tion, illness and weight loss during the last three
months. Usefulness for detecting frailty in elderly people
has been proven [99–101].
The Swallowing Disturbance Questionnaire for Detecting
Dysphagia (SDQ, [102]) is a 15-item questionnaire to detect
dysphagia. The SDQ has been shown to be reliable
(Cronbach’s alpha = 0.89) and useful to assess swal-
lowing in PD.
Different aspects of malnutrition will be measured via
interview using the Mini Nutritional Assessment (MNA,
[103]), Malnutrition Universal Screening (MUST, [104])
and Subjective Global Assessment (SGA, [105]). The in-
struments assess nutritional status based on objective
data (e.g. weight, height, Body-Mass-Index), physical
examination and the participant’s self-report.
Autonomic dysfunction
At the location of Kiel, heart rate variability (HRV) will
be examined using computer-assisted equipment (ProS-
ciCard III, MediSyst GmbH, Germany) during rest and
controlled deep breathing (six respiratory cycles per mi-
nute). Coefficient of variation, root mean square of suc-
cessive differences, mean circular resultant, expiration-
inspiration difference and E/I-ratio as well as a spectral
analysis of HRV will be quantified and compared to age-
related normal ranges of 120 healthy subjects [106].
Blood pressure (BP) and heart rate (HR) during ortho-
static exposition will be monitored after ten minutes of
supine rest on a tilt table. Patients will then be moved to
the erect position (65°) and BP and HR changes re-
corded at one, three, and five minutes of head-up tilt. A
decrease of systolic BP > 20mmHg and diastolic BP >
10mmHg within three minutes of tilting is regarded as
orthostatic hypotension [107].
Residual urine volume will be determined with the
BladderScan BVI6100 (Verathon Medical BV, The
Netherlands, [108]). Moreover, the reliable and validated
Qualiveen [109] questionnaire will be used for the
evaluation of HrQoL in patients with urinary disorders.
It covers frequency and intensity of different aspects
(limitations, constraints, fears, feelings) of urinary
dysfunction.
The German version of the Female Sexual Function
Index (FSFI-d, [110]) is a 19-item questionnaire for the
assessment of six different domains of female sexuality:
desire, arousal, lubrication, orgasm, satisfaction, and
pain. Its internal consistency (Cronbach’s alpha = 0.75–
0.95) is good to very good. The International Index of
Erectile Function (IIEF, [111]) is a self-administered
questionnaire for males and includes aspects of erectile
function, orgasm function, sexual desire, intercourse
satisfaction and overall satisfaction. The original version
(Cronbach’s alpha> 0.9, [111]) and the German transla-
tion have been shown to be reliable (Cronbach’s alpha =
0.95, [112]). As sexual function is a sensible topic also in
older adults, participants will be informed again expli-
citly that answering this questionnaire is voluntarily.
Biofluid analysis
Participants will be asked to provide blood and stool
samples for our established biobank [113]. Material will
be collected from the wards and directly brought to the
technicians responsible for the pre-processing and
storage of the material, to ensure highest quality stan-
dards of the biosamples. Blood samples will be used for
blood counts and DNA isolation, whereas stool samples
will be used for gut microbiome analysis.
Neuroimaging
We will analyse gradient echo T1-weighted sequences,
as well as T2-weighted flair sequences, susceptibility-
weighted imaging and DTI datasets collected with a
standardized protocol on a 3-T MRI. In addition, partici-
pants will be asked to provide any existing MRI data for
semi-quantitative analysis [114].
Home assessment
Those patients, who will undergo a planned inpatient
stay from a former clinical contact, will be contacted by
phone in advance. Patients interested in joining the
home assessment will be visited at their homes by staff
and introduced into this part of the study. During the
home assessment, participants will wear three wearables
(inertial measurement units IMUs, GaitUp SA,
Lausanne, Switzerland) fixed at the lower back and at
the more affected ankle and wrist (if both sides are
equally affected they wear the sensors on the right).
They will also be asked to keep a structured diary about
Geritz et al. BMC Geriatrics           (2020) 20:45 Page 7 of 13
their activities to ensure comparability of subjective
evaluation with IMU-based data. Participants will be
assessed 24 h per day over seven days before and after
the inpatient stay. In case patients may have difficulties
with the handling of the sensor system, relatives will be
asked to support the measurement process.
Database and statistics
Study data will be collected and managed using REDCap
electronic data capture tools hosted at Kiel University
[115]. Statistical analysis will be performed using estab-
lished statistical programs (e.g. R version 3.5.0, The R
Foundation; SPSS 24, SPSS Corp, Chicago IL, USA). We
abstained from providing a detailed analysis plan and
power analyses as the analysis plans will be substantially
influenced by the type of research question, and power
analyses depend on both, concrete study hypotheses
(which are given here only to a certain extent) and at
least preliminary effect sizes that are, to our best know-
ledge, not yet available for most of the Parameters
collected in this specific cohort. The use of z-scores will
ensure comparability between data sets of different cen-
tres and countries. Common descriptive and inferential
statistics and equivalent nonparametric statistics will be
used for baseline data analysis. Logistic regression will
be used to evaluate confounding factors (e.g. age, gen-
der). A pre-post comparison with correction for multiple
testing will be conducted to evaluate changes in mobil-
ity, motor function and cognition between T2 and T1.
To assess reliability and responsiveness of the assess-
ments (T1 to T0), we will use t-test and Cohen’s d after
testing for normal distribution, and extract Intra-Class-
Correlation (ICC), Standard Error of Measurement
(SEM) and Minimal Detectable Change [116]. An ex-
plorative comparison of sensor-based data with clinical
data and quantitative imaging parameters will be con-
ducted by common descriptive and inferential statistics,
(non-) parametric statistics and logistic regression.
Discussion
This study will include 1000 geriatric patients, and this
number may be increased in the course of the ongoing
recruitment due to the exploratory, prospective, modu-
lar, and observational study design. We are not aware of
a comparable endeavor in this research field. Due to the
large number of participants, data obtained from this
study will also allow sub-analyses focusing on, e.g.,
presence and absence of geriatric and non-geriatric con-
ditions and comparisons across centers.
We will collect data covering many aspects of body
structure and function, but will –in line with the CGA-
go beyond this usually well-assessed ICF component and
collect data of all five components of this WHO-
designed and most widely accepted model of health and
dysfunction [40]. The main asset of this study is in our
view that as many as possible parameters of disability
and symptomatology, from biofluid and neuroimaging,
over quantitative geriatric syndrome assessment and
parameters of autonomic and mobility dysfunctions will
be collected on a quantitative level. The broad range of
parameters will allow the use of novel analysis ap-
proaches and testing of hypotheses that can serve as an
ideal starting point for the initiation of hypothesis-
driven studies in the field of geriatrics.
This study will also evaluate treatment response
through repeated assessment at the beginning and the
end of multidisciplinary geriatric care programs. The
programs will be comparable in the majority of partici-
pants and will encompass individual allied health
training of at least 20 sessions, and re-evaluation and
adaptation of medication (in the frame of, e.g., the early
rehabilitation in geriatric medicine concept as applied in
Germany [117, 118]). This approach will allow the
definition of effective versus non-effective response-to-
treatment parameters as well as the definition of predict-
ive parameters for defined treatment approaches. This
aspect is relevant especially at times when value-based
healthcare [119, 120], precision medicine [121] and
shared decision making [122] become increasingly
important.
Moreover, we will evaluate test-retest reliability and
minimal clinically relevant change through an additional
T0 assessment. This approach is relevant in the light of
the large number of assessments and inclusion of novel
parameters in this study, to provide first evidence for the
clinical meaningfulness of these parameters but also to
provide information about the extent of noise that these
parameters have during repeated assessments.
We will also use modern technology for the assess-
ment of movement deficits, including but not limited to
gait, balance, transfers, sleep and mobility. We will only
apply algorithms that are validated for these populations
for the extraction and appraisal of movement episodes
and mobility patterns (e.g., [123–126]). It is expected
that yet unknown symptoms will be detected that are
not visible with the usual “clinical eye” [30]. We will
evaluate our participants not only in the hospitals but
will collect daily-life data during a 24/7 assessment
before and after the inpatient stay in a subgroup. This
approach will give us access to an entirely new field of
research, i.e. mobility, movement, and behavioral aspects
in the natural environment of the participants. These
measures will provide complementary aspects to the
supervised assessments in the clinic, where measures
mainly reflect functional capacity (“How well can you
perform?”), as parameters collected in the usual environ-
ment rather reflect functional activity (“How do you
regularly perform?”) [127, 128]. We have recently
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learned that “identical” behaviors and movements can
substantially differ depending on whether they are col-
lected in the clinical or the home environment [129].
The home-based dataset will also allow evaluation of
fluctuation in performance.
Limitations
This study’s limitations include: firstly, the cohort includes
old and frail people, and the assessment is somewhat ex-
haustive. Thus, it is possible that some participants lose
motivation during the first assessment or between the first
and second assessment. We will therefore split the re-
spective assessments into parts and will allow adequate
breaks (e.g. over lunch). This is possible as participants are
investigated during an inpatient stay, and assessment
times can be flexibly organized. Second, although the
treatment is highly standardized at least in the German
centers, this treatment is not comparable to standardized
treatments as they are typically performed in clinical trials.
Still, we feel that our approach is of value as this treatment
reflects the “real life situation” in the participating centers
and the high number of participants will most probably
allow analyses in similarly treated subgroups. Third, the
home assessment requires some technical understanding,
which may not always be given in all participants. We will
address this issue by asking spouses and other related
people to help with the charging of the sensors, and by
providing telephone contact in case technical issues occur.
Fourth, use of novel technology always includes the risk of
technical problems and potential data loss. We are
confident that this is a little risk as we have long-lasting
experience with the companies providing the sensors and
constant communication and support is ensured by the
manufacturers. Finally, our multi-center design requires
an intense and regular interaction between respective
principle investigators and study personnel, and highly
standardized protocols. We address these aspects by
providing all relevant documents in English, by perform-
ing personal visits at all cites to personally train the
assessments and to solve any upcoming issues, and by
regularly and randomly performed internal quality checks
of the data.
This exploratory study investigates a large sample of
geriatric patients. It uses a comprehensive, mainly quan-
titative and novel technology-oriented assessment proto-
col that is performed in the clinic and at home and thus
goes beyond the already established CGA. This study
design will allow evaluation of treatment effects. Taken
together, this study has the potential to enhance our
understanding of geriatric deficits and the intra-
individual interaction of neurological age-related dis-
eases. The dataset will also allow drawing new conclu-
sions and hypotheses about disease and treatment effects
in this vulnerable population.
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